Ruchlemer, Rosa, Ben-Ami, Ronen ORCID: 0000-0003-0628-0798, Bar-Meir, Maskit, Brown, Jennifer R., Malphettes, Marion, Mous, Rogier, Tonino, Sanne H., Soussain, Carole, Barzic, Noelie, Messina, Julia A., Jain, Preetesh ORCID: 0000-0003-2735-168X, Cohen, Regev, Hill, Brian, Mulligan, Stephen P., Nijland, Marcel, Herishanu, Yair, Benjamini, Ohad, Tadmor, Tamar, Okamoto, Koh, Arthurs, Benjamin, Gottesman, Batsheva, Kater, Arnon P., Talha, Munir, Eichhorst, Barbara, Korem, Maya, Bogot, Naama, De Boer, Fransien, Rowe, Jacob M. and Lachish, Tamar (2019). Ibrutinib-associated invasive fungal diseases in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: An observational study. Mycoses, 62 (12). S. 1140 - 1148. HOBOKEN: WILEY. ISSN 1439-0507

Full text not available from this repository.

Abstract

Background Invasive fungal diseases (IFD) are life-threatening infections most commonly diagnosed in acute leukaemia patients with prolonged neutropenia and are uncommonly diagnosed in patients with lymphoproliferative diseases. Objectives Following the initial report of aspergillosis diagnosed shortly after beginning ibrutinib for chronic lymphocytic leukaemia, a survey was developed to seek additional cases of IFD during ibrutinib treatment. Methods Local and international physicians and groups were approached for relevant cases. Patients were included if they met the following criteria: diagnosis of chronic lymphocytic leukaemia/non-Hodgkin lymphoma; proven or probable IFD; and ibrutinib treatment on the date IFD were diagnosed. Clinical and laboratory data were captured using REDCap software. Result Thirty-five patients with IFD were reported from 22 centres in eight countries: 26 (74%) had chronic lymphocytic leukaemia. The median duration of ibrutinib treatment before the onset of IFD was 45 days (range 1-540). Aspergillus species were identified in 22 (63%) of the patients and Cryptococcus species in 9 (26%). Pulmonary involvement occurred in 69% of patients, cranial in 60% and disseminated disease in 60%. A definite diagnosis was made in 21 patients (69%), and the mortality rate was 69%. Data from Israel regarding ibrutinib treated patients were used to evaluate a prevalence of 2.4% IFD. Conclusions The prevalence of IFD among chronic lymphocytic leukaemia/non-Hodgkin lymphoma patients treated with ibrutinib appears to be higher than expected. These patients often present with unusual clinical features. Mortality from IFD in this study was high, indicating that additional studies are urgently needed to identify patients at risk for ibrutinib-associated IFD.

Item Type: Journal Article
Creators:
CreatorsEmailORCIDORCID Put Code
Ruchlemer, RosaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Ben-Ami, RonenUNSPECIFIEDorcid.org/0000-0003-0628-0798UNSPECIFIED
Bar-Meir, MaskitUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Brown, Jennifer R.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Malphettes, MarionUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Mous, RogierUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Tonino, Sanne H.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Soussain, CaroleUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Barzic, NoelieUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Messina, Julia A.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Jain, PreeteshUNSPECIFIEDorcid.org/0000-0003-2735-168XUNSPECIFIED
Cohen, RegevUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Hill, BrianUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Mulligan, Stephen P.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Nijland, MarcelUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Herishanu, YairUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Benjamini, OhadUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Tadmor, TamarUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Okamoto, KohUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Arthurs, BenjaminUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Gottesman, BatshevaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Kater, Arnon P.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Talha, MunirUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Eichhorst, BarbaraUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Korem, MayaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Bogot, NaamaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
De Boer, FransienUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Rowe, Jacob M.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Lachish, TamarUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
URN: urn:nbn:de:hbz:38-126684
DOI: 10.1111/myc.13001
Journal or Publication Title: Mycoses
Volume: 62
Number: 12
Page Range: S. 1140 - 1148
Date: 2019
Publisher: WILEY
Place of Publication: HOBOKEN
ISSN: 1439-0507
Language: English
Faculty: Unspecified
Divisions: Unspecified
Subjects: no entry
Uncontrolled Keywords:
KeywordsLanguage
ASPERGILLOSIS; INFECTIONS; MONOTHERAPY; PNEUMONIA; SINUSITIS; THERAPY; RISK; CLLMultiple languages
Dermatology; MycologyMultiple languages
Refereed: Yes
URI: http://kups.ub.uni-koeln.de/id/eprint/12668

Downloads

Downloads per month over past year

Altmetric

Export

Actions (login required)

View Item View Item